2 results
Approved WMOCompleted
Primairy objective: Validating of nerve fiber length, nerve fiber density, nerve fiber branches and tortuosity of a healthy control group, sarcoidosis patients with small fiber neuroapthy and sarcoidosis patients without small fiber neuropathy.…
Approved WMOPending
The objectives of this are to establish the safety, tolerability, and preliminary efficacy of VRDN-001, and the pharmacokinetic (PK) and pharmacodynamic (PD) profiles of VRDN-001 in NHV and TED patients over a dose range of 3.0 to 20.0 mg/kg.